Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 4
1990 5
1991 9
1992 6
1993 5
1994 12
1995 5
1996 4
1997 3
1998 2
1999 7
2000 3
2001 5
2002 7
2003 4
2004 6
2005 7
2006 6
2007 10
2008 17
2009 11
2010 9
2011 26
2012 25
2013 21
2014 19
2015 21
2016 18
2017 22
2018 21
2019 16
2020 17
2021 21
2022 20
2023 13
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

364 results

Results by year

Filters applied: . Clear all
Page 1
Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021.
Kotton CN, Torre-Cisneros J; International CMV Symposium Faculty; Aguado JM, Alain S, Baldanti F, Baumann G, Boeken U, de la Calle M, Carbone J, Ciceri F, Comoli P, Couzi L, Danziger-Isakov L, Fernández-Ruiz M, Girmenia C, Grossi PA, Hirsch HH, Humar A, Kamar N, Kotton C, Ljungman P, Malagola M, Mira E, Mueller N, Sester M, Teng CJ, Torre-Cisneros J, Ussetti P, Westall G, Wolf D, Zamora M. Kotton CN, et al. Among authors: torre cisneros j. Transpl Infect Dis. 2022 Dec;24(6):e13977. doi: 10.1111/tid.13977. Epub 2022 Nov 11. Transpl Infect Dis. 2022. PMID: 36271650 Free PMC article. Review.
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: torre cisneros j. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial.
Molina J, Montero-Mateos E, Praena-Segovia J, León-Jiménez E, Natera C, López-Cortés LE, Valiente L, Rosso-Fernández CM, Herrero M, Aller-García AI, Cano Á, Gutiérrez-Gutiérrez B, Márquez-Gómez I, Álvarez-Marín R, Infante C, Roca C, Valiente-Méndez A, Pachón J, Reguera JM, Corzo-Delgado JE, Torre-Cisneros J, Rodríguez-Baño J, Cisneros JM; SHORTEN trial team. Molina J, et al. Among authors: torre cisneros j. Clin Microbiol Infect. 2022 Apr;28(4):550-557. doi: 10.1016/j.cmi.2021.09.001. Epub 2021 Sep 9. Clin Microbiol Infect. 2022. PMID: 34508886 Free article. Clinical Trial.
ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers.
Tacconelli E, Mazzaferri F, de Smet AM, Bragantini D, Eggimann P, Huttner BD, Kuijper EJ, Lucet JC, Mutters NT, Sanguinetti M, Schwaber MJ, Souli M, Torre-Cisneros J, Price JR, Rodríguez-Baño J. Tacconelli E, et al. Among authors: torre cisneros j. Clin Microbiol Infect. 2019 Jul;25(7):807-817. doi: 10.1016/j.cmi.2019.01.005. Epub 2019 Jan 29. Clin Microbiol Infect. 2019. PMID: 30708122 Free article.
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al. Among authors: torre cisneros j. JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330. JAMA. 2021. PMID: 34228774 Free PMC article.
Simvastatin in Critically Ill Patients with Covid-19.
REMAP-CAP Investigators; Hills TE, Lorenzi E, Berry LR, Shyamsundar M, Al-Beidh F, Annane D, Arabi Y, Aryal D, Au C, Beane A, Bhimani Z, Bonten M, Bradbury CA, Brunkhorst FM, Burrell A, Buxton M, Calfee CS, Cecconi M, Cheng AC, Cove ME, Detry MA, Estcourt LJ, Fitzgerald M, Goligher EC, Goossens H, Green C, Haniffa R, Harrison DA, Hashmi M, Higgins AM, Huang DT, Ichihara N, Jayakumar D, Kruger PS, Lamontagne F, Lampro L, Lawler PR, Marshall JC, Mason AJ, McGlothlin A, McGuinness S, McQuilten ZK, McVerry BJ, Mouncey PR, Murthy S, Neal MD, Nichol AD, O'Kane CM, Parke RL, Parker JC, Rabindrarajan E, Reyes LF, Rowan KM, Saito H, Santos M, Saunders CT, Seymour CW, Shankar-Hari M, Sinha P, Thompson BT, Turgeon AF, Turner AM, van de Veerdonk F, Weis S, Young IS, Zarychanski R, Lewis RJ, McArthur CJ, Angus DC, Berry SM, Derde LPG, Webb SA, Gordon AC, McAuley DF. REMAP-CAP Investigators, et al. N Engl J Med. 2023 Dec 21;389(25):2341-2354. doi: 10.1056/NEJMoa2309995. Epub 2023 Oct 25. N Engl J Med. 2023. PMID: 37888913 Free PMC article. Clinical Trial.
Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study).
Castón JJ, Cano A, Pérez-Camacho I, Aguado JM, Carratalá J, Ramasco F, Soriano A, Pintado V, Castelo-Corral L, Sousa A, Fariñas MC, Muñoz P, Abril López De Medrano V, Sanz-Peláez Ó, Los-Arcos I, Gracia-Ahufinger I, Pérez-Nadales E, Vidal E, Doblas A, Natera C, Martínez-Martínez L, Torre-Cisneros J. Castón JJ, et al. Among authors: torre cisneros j. J Antimicrob Chemother. 2022 Apr 27;77(5):1452-1460. doi: 10.1093/jac/dkac049. J Antimicrob Chemother. 2022. PMID: 35187577
[Lipodystrophies].
Fuentes Jiménez F, de la Torre Cisneros J, Pérez Jiménez F. Fuentes Jiménez F, et al. Among authors: de la torre cisneros j. Med Clin (Barc). 2002 Sep 28;119(10):390-5. doi: 10.1016/s0025-7753(02)73425-8. Med Clin (Barc). 2002. PMID: 12372173 Review. Spanish. No abstract available.
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators; Lawler PR, Derde LPG, van de Veerdonk FL, McVerry BJ, Huang DT, Berry LR, Lorenzi E, van Kimmenade R, Gommans F, Vaduganathan M, Leaf DE, Baron RM, Kim EY, Frankfurter C, Epelman S, Kwan Y, Grieve R, O'Neill S, Sadique Z, Puskarich M, Marshall JC, Higgins AM, Mouncey PR, Rowan KM, Al-Beidh F, Annane D, Arabi YM, Au C, Beane A, van Bentum-Puijk W, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Cecconi M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Ezekowitz J, Fitzgerald M, Gattas D, Godoy LC, Goossens H, Haniffa R, Harrison DA, Hills T, Horvat CM, Ichihara N, Lamontagne F, Linstrum KM, McAuley DF, McGlothlin A, McGuinness SP, McQuilten Z, Murthy S, Nichol AD, Owen DRJ, Parke RL, Parker JC, Pollock KM, Reyes LF, Saito H, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Singh V, Turgeon AF, Turner AM, Zarychanski R, Green C, Lewis RJ, Angus DC, Berry S, Gordon AC, McArthur CJ, Webb SA. Writing Committee for the REMAP-CAP Investigators, et al. JAMA. 2023 Apr 11;329(14):1183-1196. doi: 10.1001/jama.2023.4480. JAMA. 2023. PMID: 37039790 Free PMC article. Clinical Trial.
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.
Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators. Gutiérrez-Gutiérrez B, et al. Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22. Lancet Infect Dis. 2017. PMID: 28442293
364 results